Compare Globus Medical Inc. Class A Common Stock (GMED) vs Intel Corp (INTC) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Intel (INTC) trades at $98.12, down 3.19% today, amid mixed technical signals with bearish moving averages but bullish oscillators. Fundamentally, the company shows improving operational trends with three consecutive quarterly EPS beats and positive operating cash flow of $9.70B in 2025, though net income remains negative at -$267M. The stock has surged over 220% year-to-date as investors assess the progress of Intel's foundry turnaround strategy and High-NA chipmaking advancements.

Intel presents a high-risk, high-reward opportunity as the company executes its strategic pivot to a foundry model. While valuation metrics appear stretched with a P/E of 904, analyst consensus targets $111.72 suggesting 14% upside potential. Key risks include intense competition from TSMC and AMD, ongoing negative profitability, and the execution challenges of the foundry transition in a capital-intensive industry.